Beta Bionics Appoints Sean Saint as CEO and Board Member
August 15, 2022 16:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not available for sale. CONCORD, Mass., Aug. 15, 2022 ...
Type 1 Diabetes Pipeline Landscape Analysis of 80+ Companies by DelveInsight
August 08, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Type 1 Diabetes Pipeline Landscape Analysis of 80+ Companies by DelveInsight Type 1 Diabetes pipeline involves 80+ key companies continuously...
Increasing Diabetic Patient Pool to Push Sales of Insulin Storage Devices across Geographies: Fact.MR Study
August 01, 2022 19:30 ET
|
FACT.MR
Seoul, South Korea, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sales of insulin storage devices across the world are predicted to increase at a CAGR of 8.1% across the forecast period (2022-2027). In 2022,...
vTv Therapeutics Announces Investment by CinRx Pharma
July 25, 2022 07:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a...
The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions
June 09, 2022 14:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The randomized Insulin-Only Bionic Pancreas...
Blood Glucose Monitoring Devices Market to reach $28.76 Billion in 2030 with a CAGR of around 7.92%
June 02, 2022 11:28 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, United States, June 02, 2022 (GLOBE NEWSWIRE) -- Blood glucose monitoring is the utilization of a glucose meter for monitoring and identifying the overall concentration content of glucose...
Pivotal Trial Results of the iLet® Bionic Pancreas to Be Presented at the ADA’s 82nd Scientific Sessions
June 01, 2022 05:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Roy W. Beck will moderate a session: The...
Beta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer
May 10, 2022 05:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer,...
The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes
April 30, 2022 04:00 ET
|
Beta Bionics, Inc.
The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.The study population — 440 adults and children 6...
Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD
April 25, 2022 05:00 ET
|
Beta Bionics, Inc.
Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for...